Meta-analysis of the efficacy of denosumab versus alendronate in osteoporosis in postmenopausal women
DOI:
https://doi.org/10.29076/issn.2602-8360vol7iss13.2023pp111-117pKeywords:
effectiveness, monoclonal antibody, bisphosphonates, osteoporosisAbstract
Osteoporosis is a worldwide public health problem, increasing morbidity and mortality in postmenopausal women, it is essential to compare the efficacy of anti- osteoporotic agents. A meta-analysis was performed to assess the efficacy of denosumab versus alendronate in the treatment of postmenopausal women with osteoporosis. Randomized controlled clinical trials with percentage increase in total hip bone mineral density (BMD) comparing denosumab and alendronate in postmenopausal women with osteoporosis were included. A total of 3731 were classified as postmenopausal women with osteoporosis, with increases in the percentage of BMD in the total hip (4 clinical trials), 2587 patients received denosumab and 1144 alendronate. The results identified an odds ratio of 1.49 (0.9 to 2.48) with a p value of 0.11 greater than 0.05, indicating that there are no significant differences in the studies of the drugs evaluated. It is concluded that there is no statistically significant difference between the efficacy of denosumab and alendronate in the treatment of osteoporosis in postmenopausal women. However, a larger number of trials are required to corroborate the results obtained.
Downloads
References
Deeks ED. Denosumab: A Review in Postmenopausal Osteoporosis. Drugs and Aging. 2018;35(2):163-173. doi:10.1007/s40266-018-0525-7
Aspray TJ, Hill TR. Osteoporosis and the ageing skeleton. Subcell Biochem. 2019;91:453-476. doi:10.1007/978-981-13-3681-2_16
Munoz M, Varsavsky M, Aviles M. Osteoporosis: Definición. Epidemiologia. Rev Osteoporos y Metab Miner. 2010;2(Supl 3):7-9.
Miller PD, Pannacciulli N, Malouf-Sierra J, et al. Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. Osteoporos Int. 2020;31(1):181-191. doi:10.1007/s00198-019-05233-x
Anastasilakis AD, Polyzos SA, Efstathiadou ZA, et al. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers. Metabolism. 2015;64(10):1291-1297. doi:10.1016/j.metabol.2015.06.018
Tsourdi E, Makras P, Rachner TD, et al. Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. Bone. 2019;120:44-49. doi:10.1016/j.bone.2018.10.001
Carretero M. Alendronato sódico. Offarm. 2002;21(11):138-140.
Barrionuevo P, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: A network meta- analysis. J Clin Endocrinol Metab. 2019;104(5):1623-1630. doi:10.1210/jc.2019-00192
Ding LL, Wen F, Wang H, et al. Osteoporosis drugs for prevention of clinical fracture in white postmenopausal women: a network meta-analysis of survival data. Osteoporos Int. 2020;31(5):961-971. doi:10.1007/s00198-019-05183-4
Zhang L, Pang Y, Shi Y, et al. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. Menopause. 2015;22(9):1021-1025. doi:10.1097/GME.0000000000000466
Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25(1):72-81. doi:10.1359/jbmr.090716
Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153-161. doi:10.1359/jbmr.0809010
Mcclung MR, Lewiecki EM, Cohen SB, et al. con baja densidad mineral ósea. Published online 2013:821-831.
Downloads
Published
Issue
Section
License
Todos los artículos de la Revista FACSalud UNEMI son difundidos bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
Los autores mantienen los derechos de autor, y, por lo tanto, son libres de compartir, copiar, distribuir, ejecutar y comunicar públicamente la obra bajo las condiciones siguientes: Reconocer los créditos de la obra especificada por el autor e indicar si se realizaron cambios (puede hacerlo de cualquier forma razonable, pero no de una manera que sugiera que el autor respalda el uso que hace de su obra. No utilizar la obra para fines comerciales. En caso de remezcla, transformación o desarrollo, no puede distribuirse el material modificado.
